Download PDF

1. Company Snapshot

1.a. Company Description

Regeneron Pharmaceuticals, Inc.discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide.The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion.


It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma;Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults.In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions.It has collaboration and license agreements with Sanofi; Bayer; Teva Pharmaceutical Industries Ltd.; Mitsubishi Tanabe Pharma Corporation; Alnylam Pharmaceuticals, Inc.; Roche Pharmaceuticals; and Kiniksa Pharmaceuticals, Ltd., as well as has an agreement with the U.S. Department of Health and Human Services, as well as with Zai Lab Limited; Intellia Therapeutics, Inc.; Biomedical Advanced Research Development Authority; and AstraZeneca PLC.


The company was incorporated in 1988 and is headquartered in Tarrytown, New York.

Show Full description

1.b. Last Insights on REGN

Regeneron Pharmaceuticals' recent performance was driven by strong Q3 earnings, with quarterly earnings of $11.83 per share beating estimates. The company's Dupixent and oncology growth offset Eylea/Eylea HD declines. A robust pipeline and upcoming catalysts, including Phase 3 trial results for LAG3 melanoma treatment and Eylea updates, support future revenue and margin expansion. Institutional investors, such as AXQ Capital LP and Bronte Capital Management Pty Ltd, have increased their stakes in the company. Positive news from the FDA has also contributed to the stock's recent surge.

1.c. Company Highlights

2. Regeneron Pharmaceuticals' Solid Q3 Driven by Strong Product Sales

Regeneron Pharmaceuticals delivered a robust third quarter, with total revenues reaching $3.8 billion, a 1% increase compared to the prior year. The company's diluted net income per share was $11.83, surpassing estimates of $9.65, on net income of $1.3 billion. The strong financial performance was driven by double-digit net sales growth for key products, including Dupixent, Libtayo, and EYLEA HD. Dupixent worldwide net sales reached $4.9 billion, growing 26% on a constant currency basis compared to the prior year.

Publication Date: Oct -30

📋 Highlights
  • Dupixent's Global Growth:: Achieved $4.9 billion in net sales, up 26% YoY, driven by 28% growth in the U.S.
  • Libtayo's FDA Approval:: Recognized as the first PD-1 antibody for high-risk adjuvant cutaneous squamous cell carcinoma, with $365 million in global sales (24% YoY growth).
  • EYLEA HD Record Sales:: U.S. net sales reached $431 million, an all-time high, despite 10% QoQ decline in overall EYLEA U.S. sales.
  • Pipeline Advancements:: Positive Phase III data for six programs, including Dupixent's FDA submission for Allergic Fungal Rhinosinusitis and Factor XI antibodies in anticoagulation trials.
  • Gene Therapy Breakthroughs:: 11/12 treated children with OTOF gene therapy showed meaningful hearing gains; garetosmab for FOP to file for FDA approval by late 2025.

Commercial Portfolio Performance

The company's commercial portfolio is well-positioned to capitalize on near-term growth opportunities. Dupixent continues to deliver remarkable outcomes, with strong growth across approved indications and geographic regions. Libtayo delivered $365 million worldwide net sales, growing 24% on a constant currency basis compared to the prior year, following the FDA's approval for high-risk adjuvant cutaneous squamous cell carcinoma. EYLEA HD had a strong performance in the third quarter, with U.S. net product sales reaching $431 million, an all-time high.

Pipeline Progress and Upcoming Milestones

Regeneron's pipeline is poised to deliver scientific breakthroughs, with multiple important data readouts showcasing the strength of the pipeline. The company announced positive Phase III or registration-enabling data for six distinct programs spanning immunology, neurology, allergy, and rare diseases. The Factor XI antibody program is expected to provide a safer way to achieve anticoagulation, while cemdisiran in gMG offers a highly differentiated product with convenience, efficacy, and potential safety benefits.

Valuation and Growth Prospects

With a P/E Ratio of 14.78 and an EV/EBITDA of 12.23, Regeneron's valuation metrics suggest a reasonable pricing considering its growth prospects. Analysts estimate next year's revenue growth at 5.2%. The company's commitment to investing over $7 billion in infrastructure and manufacturing facilities in New York and North Carolina over the coming years is expected to drive future growth. Regeneron's strong commercial execution and advancing pipeline programs position the company for continued success.

Future Outlook

Regeneron is optimistic about finding common ground with the administration to lower the cost of medicines for American patients while preserving the United States' position as a global leader in biotech innovation and manufacturing. The company anticipates advancing multiple large registrational programs in myeloma, lymphoma, anticoagulation, obesity, and other hematology and solid tumor oncology programs in 2026.

3. NewsRoom

Card image cap

Regeneron Pharmaceuticals, Inc. $REGN Position Cut by Groupe la Francaise

Dec -04

Source: defenseworld.net

Card image cap

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Given Average Rating of “Moderate Buy” by Analysts

Dec -04

Source: defenseworld.net

Card image cap

Regeneron Pharmaceuticals, Inc. (REGN) Presents at Citi Annual Global Healthcare Conference 2025 Transcript

Dec -03

Source: seekingalpha.com

Card image cap

Here Are Wednesday’s Top Wall Street Analyst Upgrades and Downgrades: American Eagle Outfitters, Equinix, Garmin, Honeywell, Uber, Wendy’s and More

Dec -03

Source: 247wallst.com

Card image cap

Edgestream Partners L.P. Has $5.45 Million Stock Holdings in Regeneron Pharmaceuticals, Inc. $REGN

Dec -03

Source: defenseworld.net

Card image cap

Regeneron Pharmaceuticals, Inc. (REGN) Presents at Evercore 8th Annual Healthcare Conference Transcript

Dec -02

Source: seekingalpha.com

Card image cap

REGN & Tessera Collaborate to Develop Gene-Editing Therapy for AATD

Dec -02

Source: zacks.com

Card image cap

REGN Gains 21.5% in a Month: Time to Buy, Sell or Hold the Stock?

Dec -01

Source: zacks.com

4. Business Breakdown

4.a. Revenues by Country

4.b. Revenues by Segment

5. Expected revenues mid-term growth (12.30%)

6. Segments

Discovery, Development, and Commercialization of Medicines for Serious Diseases

Expected Growth: 12.3%

Regeneron's innovative pipeline and commercialization of medicines for serious diseases drive growth, with increasing focus on ophthalmology, oncology, and immunology.

7. Detailed Products

EYLEA

A vascular endothelial growth factor (VEGF) inhibitor used to treat wet age-related macular degeneration, diabetic macular edema, and diabetic retinopathy.

Dupixent

A monoclonal antibody that inhibits the action of interleukin-4 and interleukin-13, used to treat moderate-to-severe atopic dermatitis and asthma.

Praluent

A proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor used to treat high cholesterol.

Libtayo

A programmed death receptor-1 (PD-1) inhibitor used to treat cutaneous squamous cell carcinoma.

Inmazeb

A monoclonal antibody used to treat Zaire ebolavirus infection.

Evkeeza

A monoclonal antibody used to treat homozygous familial hypercholesterolemia.

8. Regeneron Pharmaceuticals, Inc.'s Porter Forces

Forces Ranking

Threat Of Substitutes

Regeneron Pharmaceuticals, Inc. has a low threat of substitutes due to its unique biotechnology products and strong research and development capabilities.

Bargaining Power Of Customers

Regeneron Pharmaceuticals, Inc. has a medium bargaining power of customers due to the presence of a large number of customers, but the company's strong brand reputation and product offerings mitigate this power.

Bargaining Power Of Suppliers

Regeneron Pharmaceuticals, Inc. has a low bargaining power of suppliers due to its strong relationships with suppliers and its ability to negotiate favorable terms.

Threat Of New Entrants

Regeneron Pharmaceuticals, Inc. has a high threat of new entrants due to the growing demand for biotechnology products and the increasing number of new entrants in the market.

Intensity Of Rivalry

Regeneron Pharmaceuticals, Inc. operates in a highly competitive industry with many established players, leading to a high intensity of rivalry.

9. SWOT Analysis

Strength

Weaknesses

Opportunities

Threats

10. Capital Structure

10.a. Balance Sheet

10.b. Weighted Average Cost of capital

Value
Debt Weight 9.43%
Debt Cost 3.95%
Equity Weight 90.57%
Equity Cost 4.78%
WACC 4.70%
Leverage 10.41%

11. Quality Control: Regeneron Pharmaceuticals, Inc. passed 9 out of 9 key points

12.a Historical Valuation

12.b Price/Earnings Ratio

12.c Margin Valuation

12.d Peers Valuation

Peers Group Analysis

Stock-Card
AbbVie

A-Score: 6.6/10

Value: 3.0

Growth: 4.7

Quality: 7.5

Yield: 7.0

Momentum: 8.5

Volatility: 9.0

1-Year Total Return ->

View Full Report
Stock-Card
McKesson

A-Score: 6.2/10

Value: 5.4

Growth: 8.3

Quality: 4.5

Yield: 0.0

Momentum: 9.5

Volatility: 9.7

1-Year Total Return ->

View Full Report
Stock-Card
Innoviva

A-Score: 4.7/10

Value: 4.9

Growth: 5.4

Quality: 6.6

Yield: 0.0

Momentum: 3.0

Volatility: 8.3

1-Year Total Return ->

View Full Report
Stock-Card
Regeneron Pharmaceuticals

A-Score: 4.2/10

Value: 4.2

Growth: 6.4

Quality: 8.6

Yield: 0.0

Momentum: 0.5

Volatility: 5.7

1-Year Total Return ->

View Full Report
Stock-Card
Vertex Pharmaceuticals

A-Score: 3.8/10

Value: 1.5

Growth: 3.9

Quality: 8.9

Yield: 0.0

Momentum: 2.0

Volatility: 6.3

1-Year Total Return ->

View Full Report
Stock-Card
Moderna

A-Score: 3.0/10

Value: 8.0

Growth: 2.3

Quality: 4.8

Yield: 0.0

Momentum: 0.5

Volatility: 2.7

1-Year Total Return ->

View Full Report

Peers Metrics

12.e Scoring Insights

12.f DCF BETA

Parameters

Short Term Growth

Short term Time

Long-Term Growth

WACC

Target Price

718.36$

Current Price

718.36$

Potential

-0.00%

Expected Cash-Flows